Pfizer To Use Cash From Sale Of OTC Unit To J&J For Biotech, Specialty Deals

Pfizer will use the cash gained through the sale of its consumer unit to Johnson & Johnson to make targeted specialty pharma and biotech acquisitions, the firm said following announcement of the deal June 26